— Key Data Readouts from Sentinel Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 and 3Q 2025 — — Initiation of RLYB116 Confirmatory PK/PD Study Expected in 2Q 2025, with Data Anticipated in 2H 2025 — — $65.5 Million in Cash, Cash Equivalents, and Marketable Securities as of December 31, 2024 Provides Runway into 2H 2026 — Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided an update on recent company developments. "We are pleased with

Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will present a corporate overview at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 1:10 p.m. EST in Boston, MA. A live webcast of the presentation will be accessible through the Events and Presentations section of Rallybio's website at www.rallybio.com. A replay of the webcast will be available for 30 days following the presentation. About Rallybio Rallybio (NASDAQ:RLYB) is a clinical-stage biotechn

– Key Data Readouts from Sentinel Participant Expected in 2Q 2025 and 3Q 2025 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the first participant has been dosed in the Phase 2 trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). Pharmacokinetic (PK) and safety data from the second trimester are expected in the second quarter of 2025, with PK and safety data at the time of delivery expected in the third quarter of 2025. "Dosing the senti

– Dosing of Sentinel (First) Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 – – Initiation of RLYB116 Confirmatory PK/PD Study Expected in 2Q 2025, with Data Anticipated in 2H 2025 – – REV102, an ENPP1 Inhibitor for the Treatment of Hypophosphatasia, to Enter IND-Enabling Studies in 2025 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today highlighted its 2024 accomplishments and announced its anticipated key milestones for 2025. "With our team's innovation and execution throughout 2024, Rallybio is well positioned to create mean

Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of two posters highlighting promising preclinical data for pipeline candidates RLYB212 and RLYB332 at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7–10, 2024 in San Diego, California. "With our Phase 2 trial underway evaluating RLYB212 in pregnant women at higher risk of maternal alloimmunization and FNAIT, we are pleased that our collaborators at Versiti continue to add to the preclinical data showing RLYB212 has the potent

-- New Biomarker Characterization Analyses Indicate RLYB116 Produced Complete and Sustained Complement Inhibition in Previous Phase 1 MAD Study – -- Manufacturing Process Enhancements Expected to Further Improve RLYB116 Tolerability -- -- Webcast Today at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced results of new biomarker characterization analyses and data from the recently completed manufacturing process enhancements for RLYB116, the Company's innovative, once-weekly, small volume, subcutaneously injected C5

— Dosing Regimen to be Evaluated in Recently Initiated RLYB212 Phase 2 Clinical Trial — Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the publication of a manuscript titled, "Informing Pregnancy Dose via Target-Mediated Drug Disposition Modeling and Simulations for a Recombinant Human Monoclonal Antibody," in a special pregnancy themed issue of Clinical Pharmacology and Therapeutics: Pharmacometrics & Systems Pharmacology. "Selecting a dose to ensure the safety of participants in any clinical trial is paramount, and not least for pregnan

Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET in Coral Gables, FL. A live webcast of the fireside chat will be accessible through the Events and Presentations section of Rallybio's website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation. About Rallybio Rallybio (NASDAQ:RLYB) is a clinical

-- Webcast to be held on Monday, December 2, 2024 at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that the Company will host a webcast to provide a program update on RLYB116, its innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor in development for the treatment of patients with complement-mediated diseases. The webcast will take place on Monday, December 2 at 8:30 AM Eastern Time and will review recent manufacturing process enhancements, biomarker characterization analyses, and the Company

— Screening is Now Underway to Identify Pregnant Women at Higher Risk for HPA-1a Alloimmunization and FNAIT — Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of its Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk for HPA-1a alloimmunization and fetal and neonatal alloimmune thrombocytopenia (FNAIT). Screening is now underway to identify the first (sentinel) pregnant woman for enrollment in the Phase 2 trial. "The initiation of screening in the RLYB212 Phase 2 trial is a significant milestone," s

JP Morgan downgraded Rallybio from Overweight to Neutral

Jefferies downgraded Rallybio from Buy to Hold and set a new price target of $1.50 from $7.00 previously

H.C. Wainwright initiated coverage of Rallybio with a rating of Buy and set a new price target of $18.00

Wedbush initiated coverage of Rallybio with a rating of Outperform and set a new price target of $17.00

JP Morgan initiated coverage of Rallybio with a rating of Overweight and set a new price target of $21.00

JMP Securities initiated coverage of Rallybio with a rating of Mkt Outperform and set a new price target of $32.00

Evercore ISI Group initiated coverage of Rallybio with a rating of Outperform and set a new price target of $40.00

Cowen initiated coverage of Rallybio with a rating of Outperform

Jefferies initiated coverage of Rallybio with a rating of Buy and set a new price target of $20.00

4 - Rallybio Corp (0001739410) (Issuer)

4 - Rallybio Corp (0001739410) (Issuer)

4 - Rallybio Corp (0001739410) (Issuer)

4 - Rallybio Corp (0001739410) (Issuer)

4 - Rallybio Corp (0001739410) (Issuer)

4 - Rallybio Corp (0001739410) (Issuer)

4 - Rallybio Corp (0001739410) (Issuer)

4 - Rallybio Corp (0001739410) (Issuer)

4 - Rallybio Corp (0001739410) (Issuer)

4 - Rallybio Corp (0001739410) (Issuer)

8-K - Rallybio Corp (0001739410) (Filer)

424B5 - Rallybio Corp (0001739410) (Filer)

10-K - Rallybio Corp (0001739410) (Filer)

8-K - Rallybio Corp (0001739410) (Filer)

8-K - Rallybio Corp (0001739410) (Filer)

SCHEDULE 13G/A - Rallybio Corp (0001739410) (Subject)

10-Q - Rallybio Corp (0001739410) (Filer)

8-K - Rallybio Corp (0001739410) (Filer)

8-K - Rallybio Corp (0001739410) (Filer)

10-Q - Rallybio Corp (0001739410) (Filer)

-- Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Rallybio's President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1, 2023. Dr. Uden will remain President and will also be appointed to Rallybio's Board of Directors. The Company does not expect to hire a replacement for Dr. Uden's current role. He will succeed Mart

-- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025 -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results

Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company's Chief Financial Officer (CFO), effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio's Co-Founder and CFO. The company announced Mr. Fryer's departure in June 2022, and following a transition period with Mr. Lieber, Mr. Fryer will depart the company on February 15, 2023. Mr. Lieber brings more than 30 years of experience as a CFO for public and private life sciences companies and an investment ban

-- Emerging data from Phase 1b study of RLYB212 shows rapid and complete elimination of transfused HPA-1a positive platelets -- -- Phase 1 study of RLYB116 ongoing; initial single dose safety, PK, and PD data expected for the 30 mg dose in the 4Q 2022 -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on recent program and corporate developments. "We continue to progress our pipeline toward planned upcoming milestones. We are pleased

Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has appointed Wendy K. Chung, M.D., Ph.D., to its Board of Directors. "Wendy is a tremendous addition to our Board of Directors. Her extensive clinical experience and deep scientific expertise will be a valued asset as we continue to advance our current product portfolio as well as bring additional candidates into our pipeline. We look forward to learning from her expertise and insights," said Martin Mackay, Ph.D., Chairman and Chief Executive Officer at Rallybi

--Company initiates an external search for its next Chief Financial Officer-- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jeffrey Fryer, CPA, will retire from his position as Chief Financial Officer (CFO). Mr. Fryer will continue to serve as Rallybio's CFO until a new CFO has been appointed and will retire from the Company following a transition period. Rallybio has initiated an external search to identify its next CFO. "On behalf of the Board of Directors, co-founder Steve Uden, and the Rallybio team, I wo

-- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis -- -- Company Announces Extension of Runway to 3Q 2025 As Part of Portfolio Prioritization -- -- Conference Call and Webcast Today at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated disea

SC 13G/A - Rallybio Corp (0001739410) (Subject)

SC 13G - Rallybio Corp (0001739410) (Subject)

SC 13G/A - Rallybio Corp (0001739410) (Subject)

SC 13G/A - Rallybio Corp (0001739410) (Subject)

SC 13D/A - Rallybio Corp (0001739410) (Subject)

SC 13G/A - Rallybio Corp (0001739410) (Subject)

SC 13G/A - Rallybio Corp (0001739410) (Subject)

SC 13G/A - Rallybio Corp (0001739410) (Subject)

SC 13G/A - Rallybio Corp (0001739410) (Subject)

SC 13G/A - Rallybio Corp (0001739410) (Subject)